Recently, a novel selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (SPPARMα) pemafibrate (mw: 490.55 g/mol, Parmodia®, K-877, Kowa, Tokyo, Japan) was approved in Japan as a therapeutic agent against hyperlipidemia. The gene discussed is PPARA; the disease is hyperlipidemia.